← all works
First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Canadian affiliationAn author listed a Canadian institution. This is the only route the usual frame has.
Abstract
No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.
The record
- Venue
- The Lancet
- Topic
- Cancer Immunotherapy and Biomarkers
- Field
- Medicine
- Canadian institutions
- Centre Hospitalier de l’Université de Montréal
- Funders
- National Cancer InstituteOno PharmaceuticalBristol-Myers Squibb
- Keywords
- MedicineGastric adenocarcinomaGastro-ChemotherapyNivolumabInternal medicineGastroenterologyOpen labelAdenocarcinomaGastroesophageal JunctionOncologyClinical trialCancerRefluxImmunotherapyDisease
- Has abstract in OpenAlex
- no